Abstract
e14506Background: Ipilimumab (anti-CTLA-4) promotes durable antitumor responses in a subset of patients with mCRPC. We designed a clinical trial (NCT02113657) to test the hypothesis that the induct...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
